• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Vasoconstriction in human isolated middle meningeal arteries: determining the contribution of 5-HT1B- and 5-HT1F-receptor activation.人离体脑膜中动脉的血管收缩:确定5-HT1B和5-HT1F受体激活的作用
Br J Clin Pharmacol. 1999 Jan;47(1):75-82. doi: 10.1046/j.1365-2125.1999.00851.x.
2
Characterization of binding, functional activity, and contractile responses of the selective 5-HT receptor agonist lasmiditan.选择性 5-HT 受体激动剂 lasmiditan 的结合、功能活性和收缩反应特征。
Br J Pharmacol. 2019 Dec;176(24):4681-4695. doi: 10.1111/bph.14832. Epub 2019 Nov 7.
3
Involvement of 5-HT(1B/1D) and 5-HT2A receptors in 5-HT-induced contraction of endothelium-denuded rabbit epicardial coronary arteries.5-羟色胺(5-HT)诱导的去内皮兔心外膜冠状动脉收缩中5-HT(1B/1D)和5-HT2A受体的作用。
Br J Pharmacol. 1997 Nov;122(5):875-84. doi: 10.1038/sj.bjp.0701470.
4
5-HT1B-receptors and vascular reactivity in human isolated blood vessels: assessment of the potential craniovascular selectivity of sumatriptan.5-羟色胺1B受体与人体离体血管的血管反应性:舒马曲坦潜在颅脑血管选择性的评估
Br J Clin Pharmacol. 2002 Mar;53(3):266-74. doi: 10.1046/j.0306-5251.2001.01536.x.
5
Characterisation of 5-HT receptors in human coronary arteries by molecular and pharmacological techniques.运用分子和药理学技术对人冠状动脉中的5-羟色胺受体进行特性分析。
Eur J Pharmacol. 1999 May 7;372(1):49-56. doi: 10.1016/s0014-2999(99)00114-4.
6
Characterization of sumatriptan-induced contractions in human isolated blood vessels using selective 5-HT(1B) and 5-HT(1D) receptor antagonists and in situ hybridization.使用选择性5-HT(1B)和5-HT(1D)受体拮抗剂及原位杂交技术对舒马曲坦诱导的人离体血管收缩进行表征。
Cephalalgia. 2002 Mar;22(2):83-93. doi: 10.1046/j.1468-2982.2002.00295.x.
7
Comparison of the vasoconstrictor effects of the selective 5-HT1D-receptor agonist L-775,606 with the mixed 5-HT1B/1D-receptor agonist sumatriptan and 5-HT in human isolated coronary artery.选择性5-HT1D受体激动剂L-775,606与5-HT1B/1D受体混合激动剂舒马曲坦及5-HT对人离体冠状动脉血管收缩作用的比较
Br J Clin Pharmacol. 2000 Feb;49(2):126-31. doi: 10.1046/j.1365-2125.2000.00129.x.
8
Contractile 5-HT1B receptors in human cerebral arteries: pharmacological characterization and localization with immunocytochemistry.人脑中动脉的收缩性5-羟色胺1B受体:药理学特性及免疫细胞化学定位
Br J Pharmacol. 1999 Nov;128(6):1133-40. doi: 10.1038/sj.bjp.0702773.
9
Operational characteristics of the 5-HT1-like receptors mediating external carotid vasoconstriction in vagosympathectomized dogs. Close resemblance to the 5-HT1D receptor subtype.去迷走交感神经犬颈外动脉血管收缩中介导5-HT1样受体的操作特性。与5-HT1D受体亚型极为相似。
Naunyn Schmiedebergs Arch Pharmacol. 1996 Nov;354(5):550-6. doi: 10.1007/BF00170827.
10
Comparison of the vasoconstrictor effects of rizatriptan and sumatriptan in human isolated cranial arteries: immunohistological demonstration of the involvement of 5-HT1B-receptors.利扎曲普坦与舒马曲坦对人离体颅动脉血管收缩作用的比较:5-HT1B受体参与的免疫组织学证明
Br J Clin Pharmacol. 1998 Dec;46(6):577-82. doi: 10.1046/j.1365-2125.1998.00821.x.

引用本文的文献

1
The 5-HT receptor as the target of ditans in migraine - from bench to bedside.5-HT 受体作为偏头痛治疗靶点的研究进展:从基础到临床。
Nat Rev Neurol. 2023 Aug;19(8):489-505. doi: 10.1038/s41582-023-00842-x. Epub 2023 Jul 12.
2
New Approaches to Shifting the Migraine Treatment Paradigm.转变偏头痛治疗模式的新方法。
Front Pain Res (Lausanne). 2022 Sep 6;3:873179. doi: 10.3389/fpain.2022.873179. eCollection 2022.
3
Cardiovascular Disease and Migraine: Are the New Treatments Safe?心血管疾病与偏头痛:新疗法安全吗?
Curr Pain Headache Rep. 2022 Aug;26(8):647-655. doi: 10.1007/s11916-022-01064-4. Epub 2022 Jun 25.
4
Lasmiditan and 5-Hydroxytryptamine in the rat trigeminal system; expression, release and interactions with 5-HT receptors.拉斯米丁和 5-羟色胺在大鼠三叉神经系统中的表达、释放及与 5-HT 受体的相互作用。
J Headache Pain. 2022 Feb 17;23(1):26. doi: 10.1186/s10194-022-01394-z.
5
International Union of Basic and Clinical Pharmacology. CX. Classification of Receptors for 5-hydroxytryptamine; Pharmacology and Function.国际基础和临床药理学联合会。CX. 5-羟色胺受体分类:药理学与功能。
Pharmacol Rev. 2021 Jan;73(1):310-520. doi: 10.1124/pr.118.015552.
6
Lasmiditan for acute treatment of migraine in patients with cardiovascular risk factors: post-hoc analysis of pooled results from 2 randomized, double-blind, placebo-controlled, phase 3 trials.拉米替坦治疗伴有心血管危险因素的偏头痛急性发作:两项随机、双盲、安慰剂对照、3 期临床试验汇总结果的事后分析。
J Headache Pain. 2019 Aug 29;20(1):90. doi: 10.1186/s10194-019-1044-6.
7
Pathophysiological Mechanisms in Migraine and the Identification of New Therapeutic Targets.偏头痛的病理生理机制及新治疗靶点的鉴定。
CNS Drugs. 2019 Jun;33(6):525-537. doi: 10.1007/s40263-019-00630-6.
8
Functional Characterization of 5-HT Receptor Drugs in Nonhuman Primates Using Simultaneous PET-MR.使用同步正电子发射断层扫描-磁共振成像技术对非人灵长类动物中5-羟色胺受体药物进行功能特性研究
J Neurosci. 2017 Nov 1;37(44):10671-10678. doi: 10.1523/JNEUROSCI.1971-17.2017. Epub 2017 Oct 2.
9
Distribution of 5-HT Receptors in Monkey Vestibular and Trigeminal Ganglion Cells.5-羟色胺受体在猴前庭神经节和三叉神经节细胞中的分布
Front Neurol. 2016 Oct 10;7:173. doi: 10.3389/fneur.2016.00173. eCollection 2016.
10
New migraine therapies promise prevention: A new generation of drugs could avert migraine attacks rather than merely relieve symptoms.新型偏头痛疗法有望实现预防:新一代药物能够避免偏头痛发作,而非仅仅缓解症状。
EMBO Rep. 2016 Jun;17(6):797-9. doi: 10.15252/embr.201642519. Epub 2016 May 6.

本文引用的文献

1
5-HT1F receptor agonists inhibit neurogenic dural inflammation in guinea pigs.5-羟色胺1F受体激动剂可抑制豚鼠的神经源性硬脑膜炎症。
Neuroreport. 1997 Jul 7;8(9-10):2237-40. doi: 10.1097/00001756-199707070-00029.
2
Sumatriptan inhibits neurogenic vasodilation of dural blood vessels in the anaesthetized rat--intravital microscope studies.舒马曲坦抑制麻醉大鼠硬脑膜血管的神经源性血管舒张——活体显微镜研究。
Cephalalgia. 1997 Jun;17(4):525-31. doi: 10.1046/j.1468-2982.1997.1704525.x.
3
Direct evidence for central sites of action of zolmitriptan (311C90): an autoradiographic study in cat.佐米曲坦(311C90)中枢作用位点的直接证据:猫的放射自显影研究
Cephalalgia. 1997 May;17(3):153-8. doi: 10.1046/j.1468-2982.1997.1703153.x.
4
The non-peptide NK-1 receptor antagonist LY303870 inhibits neurogenic dural inflammation in guinea pigs.非肽类NK-1受体拮抗剂LY303870可抑制豚鼠的神经源性硬脑膜炎症。
Life Sci. 1997;60(18):1553-61. doi: 10.1016/s0024-3205(97)00121-5.
5
Participation of 5-HT1-like and 5-HT2A receptors in the contraction of human temporal artery by 5-hydroxytryptamine and related drugs.5-羟色胺及相关药物作用下5-HT1样受体和5-HT2A受体参与人颞动脉收缩
Br J Pharmacol. 1996 Jan;117(2):283-92. doi: 10.1111/j.1476-5381.1996.tb15188.x.
6
Selective antagonism of human 5-HT1D and 5-HT1B receptor-mediated responses in stably transfected C6-glial cells by ketanserin and GR 127,935.酮色林和GR 127,935对稳定转染的C6神经胶质细胞中人5-HT1D和5-HT1B受体介导反应的选择性拮抗作用。
Eur J Pharmacol. 1996 Apr 4;300(1-2):141-5. doi: 10.1016/0014-2999(96)00011-8.
7
[3H]Sumatriptan binding sites in human brain: regional-dependent labelling of 5-HT1D and 5-HT1F receptors.人脑内的[3H]舒马曲坦结合位点:5-HT1D和5-HT1F受体的区域依赖性标记
Eur J Pharmacol. 1996 Jan 11;295(2-3):271-4. doi: 10.1016/0014-2999(95)00748-2.
8
Differential expression of sumatriptan-sensitive 5-hydroxytryptamine receptors in human trigeminal ganglia and cerebral blood vessels.舒马曲坦敏感的5-羟色胺受体在人三叉神经节和脑血管中的差异表达。
Mol Pharmacol. 1996 Aug;50(2):219-23.
9
[3H]sumatriptan labels both 5-HT1D and 5-HT1F receptor binding sites in the guinea pig brain: an autoradiographic study.[3H]舒马曲坦标记豚鼠脑中的5-HT1D和5-HT1F受体结合位点:一项放射自显影研究。
Naunyn Schmiedebergs Arch Pharmacol. 1995 Sep;352(3):263-75. doi: 10.1007/BF00168556.
10
Pharmacological characterization of acetylcholine-stimulated [35S]-GTP gamma S binding mediated by human muscarinic m1-m4 receptors: antagonist studies.人毒蕈碱型m1 - m4受体介导的乙酰胆碱刺激的[35S]-GTPγS结合的药理学特性:拮抗剂研究
Br J Pharmacol. 1993 Aug;109(4):1120-7. doi: 10.1111/j.1476-5381.1993.tb13738.x.

人离体脑膜中动脉的血管收缩:确定5-HT1B和5-HT1F受体激活的作用

Vasoconstriction in human isolated middle meningeal arteries: determining the contribution of 5-HT1B- and 5-HT1F-receptor activation.

作者信息

Razzaque Z, Heald M A, Pickard J D, Maskell L, Beer M S, Hill R G, Longmore J

机构信息

Merck Sharp & Dohme Research Laboratories, Neuroscience Research Centre, Harlow, Essex.

出版信息

Br J Clin Pharmacol. 1999 Jan;47(1):75-82. doi: 10.1046/j.1365-2125.1999.00851.x.

DOI:10.1046/j.1365-2125.1999.00851.x
PMID:10073743
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC2014192/
Abstract

AIMS

Sumatriptan is a 5-HT1B/1D-receptor agonist which also has affinity for 5-HT1F-receptors. The vasoconstrictor effects of sumatriptan are thought to be 5-HT1B-receptor mediated and these receptors have been shown to be expressed in human cranial blood vessels. However, in the same tissue mRNA coding for 5-HT1F-receptors has also been identified and this study addresses the possibility of whether 5-HT1F-receptor activation contributes to vasoconstriction.

METHODS

The ability of two selective 5-HT1B/1D-receptor antagonists (GR125,743 and GR127,935) with no affinity for 5-HT1F-receptors, to inhibit sumatriptan evoked contractions in human isolated middle meningeal artery was investigated. Using a series of 5-HT1B/1D-receptor agonists (sumatriptan, zolmitriptan, CP122,288, L-741,519 and L-741,604), some with high affinity for 5-HTIF-receptors and the non-selective 5-HT-receptor agonists 5-HT and 5-CT, we compared the vasoconstrictor potency of these drugs in human isolated middle meningeal artery with their affinities at cloned human 5-HT1B-, 5-HT1D-and 5-HT1F-receptors expressed in CHO cell lines.

RESULTS

GR125,743 antagonized sumatriptan evoked contractions in a competitive manner (apparent pA2 9.1) and GR127,935 antagonized sumatriptan-induced responses in a non-competitive manner (reducing the maximum contraction to 27%). There was a significant correlation between vasoconstrictor potency and 5-HT1B-receptor affinity (r=0.93, P=0.002) but not with 5-HT1D- or 5-HT1F-receptor affinity (r=0.74, P=0.06; r= 0.31, P= 0.49, respectively).

CONCLUSIONS

These experiments show that in human middle meningeal artery vasoconstriction to sumatriptan-like agents is 5-HT1B-receptor mediated with little if any contribution from 5-HT1F-receptor activation.

摘要

目的

舒马曲坦是一种5-HT1B/1D受体激动剂,对5-HT1F受体也有亲和力。舒马曲坦的血管收缩作用被认为是由5-HT1B受体介导的,并且这些受体已被证明在人类颅脑血管中表达。然而,在同一组织中也已鉴定出编码5-HT1F受体的mRNA,本研究探讨了5-HT1F受体激活是否有助于血管收缩的可能性。

方法

研究了两种对5-HT1F受体无亲和力的选择性5-HT1B/1D受体拮抗剂(GR125,743和GR127,935)抑制舒马曲坦诱发的人离体脑膜中动脉收缩的能力。使用一系列5-HT1B/1D受体激动剂(舒马曲坦、佐米曲坦、CP122,288、L-741,519和L-741,604),其中一些对5-HT1F受体具有高亲和力,以及非选择性5-HT受体激动剂5-HT和5-CT,我们比较了这些药物在人离体脑膜中动脉中的血管收缩效力与其在CHO细胞系中表达的克隆人5-HT1B、5-HT1D和5-HT1F受体上的亲和力。

结果

GR125,743以竞争性方式拮抗舒马曲坦诱发的收缩(表观pA2为9.1),GR127,935以非竞争性方式拮抗舒马曲坦诱导的反应(将最大收缩降低至27%)。血管收缩效力与5-HT1B受体亲和力之间存在显著相关性(r=0.93,P=0.002),但与5-HT1D或5-HT1F受体亲和力无关(r分别为0.74,P=0.06;r=0.31,P=0.49)。

结论

这些实验表明,在人脑膜中动脉中,对舒马曲坦样药物的血管收缩是由5-HT1B受体介导的,5-HTF受体激活几乎没有贡献。